AEON Biopharma raises $6M private placement, plans Daewoong note exchange for ~23M shares

AEON Biopharma, Inc.

First closing of private placement expected week of Nov 17, 2025: 1,964,905 shares/pre-funded warrants at $0.9116 per share.
Second closing subject to stockholder approval: 4,616,924 shares and 6,581,829 warrants at $1.09392.
Term sheet with Daewoong to exchange existing notes for $1.5M new note, ~23.1M shares, and 8M warrants.
True-Up Warrants issued to maintain investor ownership percentage post-Daewoong exchange.
Investors receive registration rights for resale of shares and warrant shares.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

AEON Biopharma, Inc. issued 1,964,905 Shares of common stock to certain investors for $0.9116 per Share.

Security: common stock
Shares: 1,964,905 Shares
Purchaser: certain investors
Consideration: $0.9116 per Share

Exact text from the filing

to purchase shares of Common Stock, and (iv) True-Up Warrants (as defined below) to purchase shares of Common Stock. The purchase price to be paid by the Investors will be $0.9116 per Share (or $0.9115 per Pre-Funded Warrant in lieu of Shares). The first closing of the Private Placement is expected to occur the week of November 17, 2025 (the “First

View on SEC.gov

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

AEON Biopharma, Inc. issued Pre-Funded Warrants, Warrants and True-Up Warrants of warrant to certain investors for $0.0001 per share for Pre-Funded Warrants, $1.09392 per share for Warrants.

Security: warrant
Shares: Pre-Funded Warrants, Warrants and True-Up Warrants
Purchaser: certain investors
Consideration: $0.0001 per share for Pre-Funded Warrants, $1.09392 per share for Warrants

Exact text from the filing

The Pre-Funded Warrants are being offered in lieu of shares of Common Stock and each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share.

View on SEC.gov

Browse all equity issuances →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.